SGLT2 Inhibitors

SGLT2 inhibitors were developed to treat type 2 diabetes by forcing the kidneys to excrete excess glucose in urine. They have since become one of the more consequential drug classes in modern cardiology and nephrology, and are increasingly discussed as candidate longevity drugs.

The strongest evidence is a set of large cardiovascular outcome trials run for regulatory approval, not for aging. EMPA-REG OUTCOME randomized 7,020 people with type 2 diabetes and high cardiovascular risk to empagliflozin or placebo. Over a median 3.1 years, empagliflozin reduced cardiovascular death by 38% relative risk reduction (3.7% vs 5.9%) and all-cause death by 32% (5.7% vs 8.3%), alongside a 35% relative reduction in heart failure hospitalization [1]. That is a genuine, hard-endpoint, all-cause mortality benefit in a specific population: people who already had type 2 diabetes and elevated cardiovascular risk. A 2024 healthspan-focused review compiled observational and trial data linking SGLT2 inhibition to lower risk across a wide list of age-related conditions, including heart failure, chronic kidney disease, atrial fibrillation, gout, and dementia, and proposed mechanisms involving autophagy induction, reduced oxidative stress, and improved mitochondrial function as an explanation for benefits that go beyond glucose control [2].

What the evidence does not show is a longevity effect in people without diabetes or established cardiovascular/kidney disease. Every large outcome trial, EMPA-REG, and the drug class more broadly, enrolled patients with diabetes, heart failure, or chronic kidney disease as an entry criterion. Nobody has run an SGLT2 inhibitor trial in metabolically healthy adults to test aging biomarkers or lifespan. The 2024 healthspan review itself acknowledges this gap directly, closing with a call for randomized trials to test whether SGLT2 inhibition improves healthspan and lifespan outside diagnosed disease, language that is a request for evidence that does not yet exist, not a report of it [2]. The mechanistic argument, that these drugs mimic fasting and calorie restriction by shifting metabolism toward nutrient-deprivation signaling, is plausible but has not been tested against a biological age clock in a controlled human trial.

Blueprint's public protocol does not list an SGLT2 inhibitor among Bryan Johnson's current supplements or medications; his metabolic strategy relies on diet composition and time-restricted eating rather than a prescription glucose-excretion drug, which is a meaningful absence given how much online longevity discussion treats this class as a near-consensus addition.

Critics of the longevity extrapolation point out that every mortality benefit measured so far sits inside a diabetic or cardiorenal population already at elevated baseline risk, where an intervention has more room to show benefit. Applying a 32% relative all-cause mortality reduction seen in sick patients to healthy people considering the drug preventively is an extrapolation the trial data cannot support; RCTs in healthy populations have not been run, and SGLT2 inhibitors carry real risks, including genital infections (elevated in EMPA-REG) and, more rarely, diabetic ketoacidosis, euglycemic ketoacidosis, and volume depletion, risks that are easier to justify against a large diabetic mortality benefit than against speculative healthspan gains in someone without disease.

SGLT2 inhibitors have some of the best hard-outcome human trial data of any drug discussed in longevity circles, but that data is prescription-only and disease-specific; using it as evidence for healthy-population life extension is a leap the trials themselves were not designed to test.